II 

117TH CONGRESS 

2D SESSION S. 3819 

To establish an Advanced Research Projects Authority for Health within 

the National Institutes of Health. 

IN THE SENATE OF THE UNITED STATES 

MARCH 10 (legislative day, MARCH 7), 2022 

Mrs. MURRAY (for herself and Mr. BURR) introduced the following bill; which 

was read twice and referred to the Committee on Health, Education, 

Labor, and Pensions 

A BILL 

To establish an Advanced Research Projects Authority for 

Health within the National Institutes of Health. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Advanced Research 

5 Project Authority for Health Act’’ or the ‘‘ARPA–H Act’’. 

6 SEC. 2. ADVANCED RESEARCH PROJECTS AUTHORITY FOR 

7 HEALTH. 

8 Part E of title IV of the Public Health Service Act 

9 (42 U.S.C. 287 et seq.) is amended by inserting after sub10 part 2 of such part the following: 


pamtmann on DSKBC07HB2PROD with BILLS
2 

•S 3819 IS

1 ‘‘Subpart 3—Advanced Research Projects Authority 

2 for Health 

3 ‘‘SEC. 483. ADVANCED RESEARCH PROJECTS AUTHORITY 

4 FOR HEALTH. 

5 ‘‘(a) DEFINITIONS.—In this section: 

6 ‘‘(1) ARPA–H.—The term ‘ARPA–H’ means 

7 the Advanced Research Projects Authority for 

8 Health established under subsection (b). 

9 ‘‘(2) DIRECTOR.—The term ‘Director’ means 

10 the Director of ARPA–H appointed under sub11 section (c). 

12 ‘‘(3) OTHER TRANSACTIONS.—The term ‘other 

13 transactions’ has the meaning given such term in 

14 section 319L(a)(3). 

15 ‘‘(b) ESTABLISHMENT OF THE ADVANCED RE16 SEARCH PROJECTS AUTHORITY FOR HEALTH.—There is 

17 established within the National Institutes of Health the 

18 Advanced Research Projects Authority for Health, for 

19 purposes of— 

20 ‘‘(1) supporting high-impact, cutting-edge re21 search in biomedicine and broadly applicable break22 through technologies that have the potential to sig23 nificantly transform and advance areas of biomedical 

24 science and medicine in a manner that cannot read25 ily be accomplished through traditional biomedical 

26 research or commercial activity; and 


pamtmann on DSKBC07HB2PROD with BILLS
3 

•S 3819 IS

1 ‘‘(2) overcoming long-term and significant tech2 nological and scientific barriers to advancing such 

3 technologies in order to improve the prevention, di4 agnosis, mitigation, treatment, and cure of health 

5 conditions. 

6 ‘‘(c) DIRECTOR.— 

7 ‘‘(1) IN GENERAL.—ARPA–H shall be headed 

8 by a Director, who shall be appointed by the Presi9 dent. The Director shall report to the Director of 

10 NIH. 

11 ‘‘(2) QUALIFICATIONS.—The Director shall be 

12 an individual who, by reason of professional back13 ground and experience, is especially qualified to ad14 vise the Secretary on, and manage, research pro15 grams that advance the purposes of ARPA–H in 

16 promoting biomedical and novel technology innova17 tion pursuant to this section, and who has a dem18 onstrated ability to identify and develop partnerships 

19 to address strategic needs in meeting such purposes. 

20 ‘‘(3) APPOINTMENT.—Notwithstanding section 

21 405(a)(2), the Director shall be appointed for a pe22 riod of 4 years. The President may extend the term 

23 of a Director for a period of up to 4 additional 

24 years. 

25 ‘‘(4) DUTIES.—The Director shall— 


pamtmann on DSKBC07HB2PROD with BILLS
4 

•S 3819 IS

1 ‘‘(A) establish strategic goals, objectives, 

2 and priorities for ARPA–H, pursuant to the 

3 purposes of ARPA–H described in subsection 

4 (b); 

5 ‘‘(B) approve all new programs within 

6 ARPA–H and terminate any program within 

7 ARPA–H that is not achieving its goals; 

8 ‘‘(C) establish criteria for funding and as9 sessing the success of programs through the es10 tablishment of technical milestones; 

11 ‘‘(D) ensure that applications for funding 

12 disclose current and previous research and de13 velopment efforts, and identify any challenges 

14 associated with such efforts, including any sci15 entific or technical barriers encountered in the 

16 course of such efforts or challenges in securing 

17 sources of funding, as applicable and appro18 priate, in pursuit of the technology area for 

19 which funding is requested; 

20 ‘‘(E) facilitate coordination between the 

21 Department of Health and Human Services, 

22 relevant agencies within such Department, and 

23 other relevant Federal departments and agen24 cies, with respect to research supported by 

25 ARPA–H; 


pamtmann on DSKBC07HB2PROD with BILLS
5 

•S 3819 IS

1 ‘‘(F) support transformative, translational, 

2 applied, and advanced research in areas of bio3 medical science to address specific technical or 

4 scientific questions by— 

5 ‘‘(i) prioritizing investments based on 

6 scientific potential and impact on the field 

7 of biomedicine, as described in subsection 

8 (b), especially in areas that require public9 private partnerships in order to effectively 

10 advance research and development activi11 ties; 

12 ‘‘(ii) translating scientific discoveries 

13 and cutting-edge innovation into techno14 logical advancements; 

15 ‘‘(iii) encouraging opportunities to de16 velop broadly applicable technologies, using 

17 a multi-disciplinary approach; and 

18 ‘‘(iv) making investments in high-risk, 

19 high-reward research related to broadly ap20 plicable technologies, capabilities, and plat21 forms that may have an application for 

22 medicine and health; 

23 ‘‘(G) encourage strategic collaboration and 

24 partnerships with a broad range of entities, in25 cluding institutions of higher education, indusVerDate Sep 11 2014 16:56 Mar 14, 2022 Jkt 029200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6201 E:\BILLS\S3819.IS S3819

pamtmann on DSKBC07HB2PROD with BILLS
6 

•S 3819 IS

1 try, nonprofit organizations, or consortia of 

2 such entities, which may include federally fund3 ed research and development centers; and 

4 ‘‘(H) ensure that the United States main5 tains global leadership in researching and devel6 oping health technologies. 

7 ‘‘(d) PERSONNEL.— 

8 ‘‘(1) IN GENERAL.—The Director shall establish 

9 and maintain within ARPA–H a staff with appro10 priate qualifications and expertise to enable ARPA– 

11 H to carry out the responsibilities under this section. 

12 ‘‘(2) PROGRAM MANAGERS.— 

13 ‘‘(A) IN GENERAL.—The Director shall 

14 designate employees to serve as program man15 agers for the programs established or supported 

16 pursuant to subsection (c)(4). 

17 ‘‘(B) RESPONSIBILITIES.—A program 

18 manager shall— 

19 ‘‘(i) establish, in consultation with the 

20 Director, research and development goals 

21 for the program, including timelines and 

22 milestones, and make such goals available 

23 to the public; 


pamtmann on DSKBC07HB2PROD with BILLS
7 

•S 3819 IS

1 ‘‘(ii) provide project oversight and 

2 management of strategic initiatives to ad3 vance the purpose of the program; 

4 ‘‘(iii) encourage research collabora5 tions, including by identifying and sup6 porting applicable public-private partner7 ships; 

8 ‘‘(iv) select the projects to be sup9 ported under the program after consid10 ering— 

11 ‘‘(I) the novelty, scientific, and 

12 technical merit of the proposed 

13 projects; 

14 ‘‘(II) the demonstrated capabili15 ties of the applicants to successfully 

16 carry out the proposed project and 

17 achieve designated milestones within 

18 the applicable timeline; 

19 ‘‘(III) the potential future com20 mercial applications of the project 

21 proposed by the applicant; 

22 ‘‘(IV) the degree to which the 

23 project addresses a scientific or tech24 nical question pursuant to subsection 

25 (c)(4)(F) and has the potential to 


pamtmann on DSKBC07HB2PROD with BILLS
8 

•S 3819 IS

1 transform biomedicine, as described in 

2 subsection (b); and 

3 ‘‘(V) other criteria as established 

4 by the Director; 

5 ‘‘(v) recommend program restructure, 

6 expansion, or termination of research 

7 projects or whole projects, as necessary 

8 and appropriate; and 

9 ‘‘(vi) communicate with leaders in the 

10 health care and biomedical research and 

11 development fields, including from both the 

12 public and private sectors, representatives 

13 of patient organizations, institutions of 

14 higher education, and nonprofit organiza15 tions, to identify areas of need and sci16 entific opportunity with the potential to 

17 transform biomedicine as described in sub18 section (b). 

19 ‘‘(C) TERM.—The term of a program man20 ager shall be not more than 3 years, and, at the 

21 discretion of the Director, may be renewed for 

22 one additional period of up to 3 years. 

23 ‘‘(3) CONSIDERATIONS.—The Director— 

24 ‘‘(A) in designating employees to serve as 

25 program managers under paragraph (1), shall 


pamtmann on DSKBC07HB2PROD with BILLS
9 

•S 3819 IS

1 consider, as appropriate, individuals with dem2 onstrated scientific expertise and management 

3 skills required to advance the purposes of 

4 ARPA–H, and who represent a diverse set of 

5 professional experiences or backgrounds, includ6 ing individuals with experience in academia, in7 dustry, government, nonprofit organizations, or 

8 other sectors; and 

9 ‘‘(B) in making appointments of personnel 

10 to staff or support ARPA–H, may consider 

11 other factors, as appropriate, such as popu12 lations that are traditionally underrepresented 

13 in the biomedical research enterprise. 

14 ‘‘(4) HIRING.— 

15 ‘‘(A) IN GENERAL.—The Director may— 

16 ‘‘(i) make or rescind appointments of 

17 scientific, medical, and professional per18 sonnel, without regard to any provision of 

19 title 5, United States Code governing ap20 pointments under the civil service laws and 

21 notwithstanding section 202 of the Depart22 ment of Health and Human Services Ap23 propriations Act, 1993 (Public Law 102– 

24 394); and 


pamtmann on DSKBC07HB2PROD with BILLS
10 

•S 3819 IS

1 ‘‘(ii) fix the compensation of such per2 sonnel at a rate to be determined by the 

3 Director, up to the amount of annual com4 pensation (excluding expenses) specified in 

5 section 102 of title 3, United States Code. 

6 ‘‘(B) REPORTING.—The Director shall es7 tablish and maintain records regarding the use 

8 of the authority under subparagraph (A)(i), in9 cluding— 

10 ‘‘(i) the number of positions filled 

11 through such authority; 

12 ‘‘(ii) the types of appointments of 

13 such positions; 

14 ‘‘(iii) the titles, occupational series, 

15 and grades of such positions; 

16 ‘‘(iv) the number of positions publicly 

17 noticed to be filled under such authority; 

18 ‘‘(v) the number of qualified appli19 cants who apply for such positions; 

20 ‘‘(vi) the qualification criteria for such 

21 positions; and 

22 ‘‘(vii) the demographic information of 

23 individuals appointed to such positions. 

24 ‘‘(C) REPORTS TO CONGRESS.—Not later 

25 than one year after the date of enactment of 


pamtmann on DSKBC07HB2PROD with BILLS
11 

•S 3819 IS

1 the Advanced Research Project Authority for 

2 Health Act, and annually thereafter for each 

3 fiscal year in which such authority is used, the 

4 Director shall submit to the Committee on 

5 Health, Education, Labor, and Pensions of the 

6 Senate and the Committee on Energy and Com7 merce of the House of Representatives a report 

8 describing the total number of appointments 

9 filled under this subsection within the fiscal 

10 year and how the positions relate to the pur11 poses of ARPA–H. 

12 ‘‘(D) PRIVATE RECRUITING FIRMS.—The 

13 Director may contract with private recruiting 

14 firms for the hiring of qualified technical staff 

15 to carry out this section. 

16 ‘‘(E) CLARIFICATIONS.— 

17 ‘‘(i) PREVIOUS POSITIONS.—The Di18 rector shall ensure that the personnel who 

19 are appointed to staff or support ARPA– 

20 H are individuals who, at the time of ap21 pointment and for 3 years prior to such 

22 appointment, were not employed by the 

23 National Institutes of Health. 

24 ‘‘(ii) NUMBER OF PERSONNEL.—The 

25 Director may appoint not more than 120 


pamtmann on DSKBC07HB2PROD with BILLS
12 

•S 3819 IS

1 personnel under this section. The Director 

2 shall submit a notification to Congress if 

3 the Director determines that additional 

4 personnel are required to carry out this 

5 section. 

6 ‘‘(F) GAO REPORT.—Not later than 2 

7 years after the date of enactment of the Ad8 vanced Research Project Authority for Health 

9 Act, the Comptroller General of the United 

10 States shall submit to the Committee on 

11 Health, Education, Labor, and Pensions of the 

12 Senate and the Committee on Energy and Com13 merce of the House of Representatives a report 

14 on the use of the authority provided under sub15 paragraph (A)(i). Such report shall, in a man16 ner that protects personal privacy, to the extent 

17 required by applicable Federal and State pri18 vacy law, at a minimum, include information 

19 on— 

20 ‘‘(i) the number of positions publicly 

21 noticed and filled under the authority 

22 under this subsection; 

23 ‘‘(ii) the occupational series, grades, 

24 and types of appointments of such posi25 tions; 


pamtmann on DSKBC07HB2PROD with BILLS
13 

•S 3819 IS

1 ‘‘(iii) how such positions related to ad2 vancing the purposes of ARPA–H; 

3 ‘‘(iv) how the Director made appoint4 ment decisions under this subsection; 

5 ‘‘(v) sources used to identify can6 didates for filling such positions; 

7 ‘‘(vi) the number of individuals ap8 pointed; 

9 ‘‘(vii) aggregated demographic infor10 mation related to individuals appointed; 

11 and 

12 ‘‘(viii) any challenges, limitations, or 

13 gaps related to the use of the authority 

14 under this subsection and any related rec15 ommendations to address such challenges, 

16 limitations, or gaps. 

17 ‘‘(e) FUNDING AWARDS.— 

18 ‘‘(1) IN GENERAL.—In carrying out this sec19 tion, the Director may award grants, contracts, co20 operative agreements, cash prizes, and enter into 

21 other transactions, as described in paragraph (2). 

22 ‘‘(2) OTHER TRANSACTIONS.— 

23 ‘‘(A) LIMITATIONS ON ENTERING INTO

24 OTHER TRANSACTIONS.— 


pamtmann on DSKBC07HB2PROD with BILLS
14 

•S 3819 IS

1 ‘‘(i) IN GENERAL.—To the maximum 

2 extent practicable, competitive procedures 

3 shall be used when entering into other 

4 transactions to carry out projects under 

5 this section. 

6 ‘‘(B) WRITTEN DETERMINATIONS RE7 QUIRED.—The authority of this paragraph may 

8 be exercised for a project if the project man9 ager— 

10 ‘‘(i) submits a proposal to the Direc11 tor for each individual use of such author12 ity before conducting or supporting a 

13 project, including why the use of such au14 thority is essential to promoting the suc15 cess of the project; 

16 ‘‘(ii) receives approval for the use of 

17 such authority from the Director; and 

18 ‘‘(iii) for each year in which the pro19 gram manager has used such authority in 

20 accordance with this paragraph, submits a 

21 report to the Director on the activities of 

22 the program relating to such project. 

23 ‘‘(3) PRIZE COMPETITIONS.—The Director may 

24 utilize the authorities and processes established 

25 under section 24 of the Stevenson-Wydler TechVerDate Sep 11 2014 16:56 Mar 14, 2022 Jkt 029200 PO 00000 Frm 00014 Fmt 6652 Sfmt 6201 E:\BILLS\S3819.IS S3819

pamtmann on DSKBC07HB2PROD with BILLS
15 

•S 3819 IS

1 nology Innovation Act of 1980 (15 U.S.C. 3719) to 

2 support prize competitions, in accordance with this 

3 section. 

4 ‘‘(4) FEDERAL DEMONSTRATION OF TECH5 NOLOGIES.—The Director may seek opportunities to 

6 partner with procurement programs of Federal agen7 cies to demonstrate technologies resulting from ac8 tivities funded through ARPA–H. 

9 ‘‘(5) CLARIFICATIONS.—Research supported by 

10 this section shall not be subject to the requirements 

11 of section 406(a)(3)(A)(ii) or 492. 

12 ‘‘(f) COORDINATION, COLLABORATION, NONDUPLICA13 TION, AND CONSULTATION.— 

14 ‘‘(1) COORDINATION.—To the maximum extent 

15 practicable, the Director shall ensure that the activi16 ties of ARPA–H are coordinated with, and do not 

17 duplicate the efforts of— 

18 ‘‘(A) other programs within, or research 

19 conducted or supported by, the Department of 

20 Health and Human Services, including the Na21 tional Institutes of Health and the Biomedical 

22 Advanced Research and Development Authority; 

23 and 

24 ‘‘(B) other relevant efforts or research and 

25 development programs operated or overseen by 


pamtmann on DSKBC07HB2PROD with BILLS
16 

•S 3819 IS

1 other departments, agencies, or offices of the 

2 Federal Government. 

3 ‘‘(2) FUNDING DETERMINATIONS.—The Direc4 tor shall ensure that ARPA–H does not provide 

5 funding for a research program or project unless the 

6 applicant for such funding demonstrates that— 

7 ‘‘(A)(i) such applicant has made sufficient 

8 unsuccessful attempts to secure private financ9 ing, and that there is a lack of significant pri10 vate support for the program or project; or 

11 ‘‘(ii) such program or project is in the best 

12 interests of the United States; and 

13 ‘‘(B) such program or project has the po14 tential to significantly transform and advance 

15 the field of biomedicine, as described in sub16 section (b). 

17 ‘‘(3) CONSULTATION.—In carrying out this sec18 tion, the Director may seek input from— 

19 ‘‘(A) the President’s Council of Advisors 

20 on Science and Technology; 

21 ‘‘(B) representatives of professional or sci22 entific organizations with expertise in specific 

23 technologies under consideration or development 

24 by ARPA–H; and 


pamtmann on DSKBC07HB2PROD with BILLS
17 

•S 3819 IS

1 ‘‘(C) representatives of patient organiza2 tions, public health, innovators, and other pub3 lic and private entities. 

4 ‘‘(4) ENHANCED COLLABORATION AND COMMU5 NICATION.— 

6 ‘‘(A) IN GENERAL.—In order to facilitate 

7 enhanced collaboration and communication with 

8 respect to the most current priorities of ARPA– 

9 H, the Food and Drug Administration may 

10 meet with ARPA–H and any other appropriate 

11 Federal partners, such as the Biomedical Ad12 vanced Research and Development Authority, at 

13 appropriate intervals, to discuss the develop14 ment status, and actions that may be taken to 

15 facilitate the development, of medical products 

16 and projects that are the highest priorities to 

17 ARPA–H. 

18 ‘‘(B) RELATION TO OTHERWISE AUTHOR19 IZED ACTIVITIES OF THE FOOD AND DRUG AD20 MINISTRATION.—Utilizing interagency agree21 ments or other appropriate resource allocation 

22 mechanisms available, the Director shall reim23 burse the Food and Drug Administration, as 

24 appropriate, for activities identified by the 

25 Commissioner of Food and Drugs and the DiVerDate Sep 11 2014 16:56 Mar 14, 2022 Jkt 029200 PO 00000 Frm 00017 Fmt 6652 Sfmt 6201 E:\BILLS\S3819.IS S3819

pamtmann on DSKBC07HB2PROD with BILLS
18 

•S 3819 IS

1 rector as being conducted by the Food and 

2 Drug Administration under the authority of 

3 this section, using funds made available to 

4 ARPA–H. 

5 ‘‘(g) ADVISORY COMMITTEE.— 

6 ‘‘(1) IN GENERAL.—There is established an 

7 ARPA–H Interagency Advisory Committee (referred 

8 to in this subsection as the ‘Advisory Committee’) to 

9 coordinate efforts and provide advice and assistance 

10 on specific program or project tasks and the overall 

11 direction of ARPA–H. 

12 ‘‘(2) MEMBERS.—The Advisory Committee es13 tablished under paragraph (1) shall consist of the 

14 heads of the following agencies or their designees: 

15 ‘‘(A) The National Institutes of Health. 

16 ‘‘(B) The Centers for Disease Control and 

17 Prevention. 

18 ‘‘(C) The Food and Drug Administration. 

19 ‘‘(D) The Office of the Assistant Secretary 

20 for Preparedness and Response. 

21 ‘‘(E) The Office of the Assistant Secretary 

22 of Health. 

23 ‘‘(F) The Defense Advanced Research 

24 Projects Agency. 


pamtmann on DSKBC07HB2PROD with BILLS
19 

•S 3819 IS

1 ‘‘(G) The Office of Science of the Depart2 ment of Energy. 

3 ‘‘(H) The National Science Foundation. 

4 ‘‘(I) Any other agency with subject matter 

5 expertise that the Director of ARPA–H deter6 mines appropriate to advance programs or 

7 projects under this section. 

8 ‘‘(3) NONAPPLICABILITY OF FACA.—The Fed9 eral Advisory Committee Act (5 U.S.C. App.) shall 

10 not apply to the Advisory Committee. 

11 ‘‘(4) ADVISORY NATURE.—The functions of the 

12 Advisory Committee shall be advisory in nature, and 

13 nothing in this subsection shall be construed as 

14 granting such Committee authority over the activi15 ties authorized under this section. 

16 ‘‘(5) PERFORMANCE MEASURES FRAMEWORK.— 

17 The Director, in consultation with the Advisory 

18 Committee, shall develop a performance measures 

19 framework for programs or projects supported by 

20 ARPA–H in order to inform and facilitate the eval21 uation required under subsection (m), including 

22 identification of any data needed to perform such 

23 evaluation, consistent with subsection (l). 

24 ‘‘(h) FACILITIES.— 


pamtmann on DSKBC07HB2PROD with BILLS
20 

•S 3819 IS

1 ‘‘(1) AUTHORITIES.—The Director is author2 ized to— 

3 ‘‘(A) acquire (by purchase, lease, con4 demnation or otherwise), construct, improve, re5 pair, operate, and maintain such real and per6 sonal property as are necessary to carry out 

7 this section; and 

8 ‘‘(B) lease an interest in property for not 

9 more than 20 years, notwithstanding section 

10 1341(a)(1) of title 31, United States Code. 

11 ‘‘(2) LOCATIONS.— 

12 ‘‘(A) IN GENERAL.—ARPA–H, including 

13 its headquarters, shall not be located, including 

14 headquartered, inside of, or in close proximity 

15 to, the National Capital region, and shall not be 

16 located on any part of the National Institutes 

17 of Health campuses. 

18 ‘‘(B) CONSIDERATIONS.—In determining 

19 the location of facilities, the Director shall con20 sider the characteristics of the intended location 

21 and the extent to which such location will facili22 tate advancement of the ARPA–H purposes 

23 pursuant to subsection (b). 

24 ‘‘(i) RULE OF CONSTRUCTION.—The authorities 

25 granted by this section— 


pamtmann on DSKBC07HB2PROD with BILLS
21 

•S 3819 IS

1 ‘‘(1) are in addition to existing authorities 

2 granted to the Secretary; and 

3 ‘‘(2) shall not be construed to modify or super4 sede any existing authorities. 

5 ‘‘(j) PROTECTION OF INFORMATION.— 

6 ‘‘(1) IN GENERAL.—Nothing in this section 

7 shall be construed as authorizing the Secretary to 

8 disclose any information that is a trade secret, or 

9 other privileged or confidential information subject 

10 to section 552(b)(4) of title 5, United States Code, 

11 or section 1905 of title 18, United States Code. 

12 ‘‘(2) REPORTING.—One year after the date of 

13 enactment of the Advanced Research Project Au14 thority for Health Act, and annually thereafter, the 

15 Director shall report to the Committee on Health, 

16 Education, Labor, and Pensions of the Senate and 

17 the Committee on Energy and Commerce of the 

18 House of Representatives on— 

19 ‘‘(A) the number of instances in which the 

20 Secretary has used the authority under this 

21 subsection to withhold information from disclo22 sure; and 

23 ‘‘(B) the nature of any request under sec24 tion 552 of title 5, United States Code, or secVerDate Sep 11 2014 16:56 Mar 14, 2022 Jkt 029200 PO 00000 Frm 00021 Fmt 6652 Sfmt 6201 E:\BILLS\S3819.IS S3819

pamtmann on DSKBC07HB2PROD with BILLS
22 

•S 3819 IS

1 tion 1905 of title 18, United States Code, that 

2 was denied using such authority. 

3 ‘‘(k) REPORTS AND STRATEGIC PLANS.— 

4 ‘‘(1) ANNUAL REPORT.—As part of the annual 

5 budget request submitted for each fiscal year, the 

6 Director shall provide to the Committee on Health, 

7 Education, Labor, and Pensions and the Committee 

8 on Appropriations of the Senate and the Committee 

9 on Energy and Commerce and the Committee on 

10 Appropriations of the House of Representatives a re11 port that describes— 

12 ‘‘(A) projects supported by ARPA–H dur13 ing the previous fiscal year, and, with respect to 

14 each such project, the stage of development and 

15 details as to whether the project is meeting 

16 project milestones; 

17 ‘‘(B) projects supported by ARPA–H in 

18 the previous fiscal year that were terminated, 

19 and the reasons for termination; 

20 ‘‘(C) projects supported by ARPA–H dur21 ing the previous fiscal year that examine topics 

22 and technologies closely related to other activi23 ties funded by the Department of Health and 

24 Human Services, including an analysis of 

25 whether in supporting such projects, the DirecVerDate Sep 11 2014 16:56 Mar 14, 2022 Jkt 029200 PO 00000 Frm 00022 Fmt 6652 Sfmt 6201 E:\BILLS\S3819.IS S3819

pamtmann on DSKBC07HB2PROD with BILLS
23 

•S 3819 IS

1 tor is in compliance with the requirements of 

2 this section; and 

3 ‘‘(D) current, proposed, and planned 

4 projects to be carried out. 

5 ‘‘(2) STRATEGIC PLAN.—Not later than 180 

6 days after the appointment of the first Director pur7 suant to subsection (c), and every 4 years thereafter, 

8 the Director shall provide to the Committee on 

9 Health, Education, Labor, and Pensions and the 

10 Committee on Appropriations of the Senate and the 

11 Committee on Energy and Commerce and the Com12 mittee on Appropriations of the House of Represent13 atives a plan describing the strategic plan that 

14 ARPA–H will use to guide future investments over 

15 the following 4 fiscal years. Every 2 years after the 

16 date of submission of the initial plan, the Director 

17 shall submit a supplemental strategic plan that de18 tails any changes to such strategic vision, as appro19 priate. The requirements regarding individual insti20 tute and center strategic plans under section 

21 402(m), including paragraph (3) of such subsection, 

22 shall not apply to ARPA–H. 

23 ‘‘(l) NATIONAL ACADEMIES OF SCIENCES, ENGI24 NEERING, AND MEDICINE EVALUATION.— 


pamtmann on DSKBC07HB2PROD with BILLS
24 

•S 3819 IS

1 ‘‘(1) IN GENERAL.—Not later than 3 years 

2 after the date of enactment of the Advanced Re3 search Project Authority for Health Act, the Direc4 tor shall seek to enter into a contract with the Na5 tional Academies of Sciences, Engineering, and Med6 icine under which the National Academies conducts 

7 an evaluation of ARPA–H regarding the goals and 

8 purposes of ARPA–H and the degree to which the 

9 activities of ARPA–H support, and align with, such 

10 goals and purposes. 

11 ‘‘(2) INCLUSIONS.—The evaluation under para12 graph (1) may include— 

13 ‘‘(A) recommendations on how to improve 

14 upon the operation of, and projects carried out 

15 by, ARPA–H, which may include lessons 

16 learned from other advanced research and de17 velopment agencies or authorities within the 

18 Department of Health and Human Services and 

19 in other departments, agencies, or offices of the 

20 Federal Government; 

21 ‘‘(B) a description of lessons learned from 

22 the establishment and operation of ARPA–H, 

23 and the manner in which those lessons may 

24 apply to the operation of other programs of the 


pamtmann on DSKBC07HB2PROD with BILLS
25 

•S 3819 IS

1 Department of Health and Human Services; 

2 and 

3 ‘‘(C) an analysis of whether any projects 

4 supported by ARPA–H were duplicative of 

5 other research programs supported by the De6 partment of Health and Human Services or 

7 other another relevant Federal department or 

8 agency. 

9 ‘‘(3) AVAILABILITY.—Upon completion of the 

10 evaluation, the evaluation shall be submitted by the 

11 Director to the Committee on Health, Education, 

12 Labor, and Pensions and the Committee on Appro13 priations of the Senate and the Committee on En14 ergy and Commerce and the Committee on Appro15 priations of the House of Representatives and made 

16 publicly available. 

17 ‘‘(m) AUTHORIZATION OF APPROPRIATIONS.—To 

18 carry out this section, there are authorized to be appro19 priated such sums as may be necessary for each of fiscal 

20 years 2023 through 2027. 

21 ‘‘(n) ADDITIONAL BUDGET CLARIFICATION.—Any 

22 budget request for ARPA–H shall be separate from the 

23 other budget requests of the National Institutes of 

24 Health.’’. 

Æ 


pamtmann on DSKBC07HB2PROD with BILLS